1AI Shares Algorae Pharmaceuticals Limited
ASX · ASXLast in our picks 2026-09-24 — not in the current list; analysis below is from that screen
Only marginally semiconductor-related; better suited to broader tech exposure than this category.
Signal breakdown
- ▸Category mismatch and limited semiconductor-specific catalysts.
- ▾Below 50-day MA (-18.4%)
- ▾Near 52-week low (6.2% of range)
Is 1AI a buy right now?
Trend: 1AI is trading below the 50-day average (-10.00%), RSI 25 — oversold territory, with a 3-month return of -25.00%.
Valuation & quality: Algorae Pharmaceuticals Limited trades on price-to-book 4.50; fundamentals show net margin 0.0%, return on equity -83.5%.
Our screen: WATCH (score 0) — Only marginally semiconductor-related; better suited to broader tech exposure than this category.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | -50.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Semiconductors picks
Browse: all ASX stocks · Semiconductors picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.